<DOC>
	<DOCNO>NCT02586350</DOCNO>
	<brief_summary>To compare effect safety Anlotinib placebo patient Medullary Thyroid Carcinoma .</brief_summary>
	<brief_title>Study Anlotinib Patients With Medullary Thyroid Carcinoma ( ALTER01031 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>1 . Signed date informed consent 2 . Histological documentation medullary thyroid carcinoma ( MTC ) , Unable surgery ( Stage IV ) metastasis , With measurable disease ( use RECIST1.1 ) 3 . ECOG PS:01 , Life expectancy 6 month 4. main organ function normal 1 . Prior treatment Anlotinib VEGFRtargeted therapy ( Vandetanib , Cabozantinib , Lenvatinib , Sunitinib , Sorafenib etc . ) 2 . Subjects receive radiotherapy external exposure within 3 month prior first dose study drug plan receive anticancer treatment study 3 . Patients suffer malignancy currently within 5 year , except cured cervical carcinoma situ , nonmelanoma skin cancer superficial bladder cancer [ Ta ( noninvasive carcinoma ) , Tis ( carcinoma situ ) T1 ( carcinoma invasion lamina propria ) ] 4 . CTCAE ( 4.0 ) Grade 1 high nonremission toxicity induce previous treatments，excluding alopecia Grade 2 low neurotoxicity induce oxaliplatin 5 . Patients factor could affect oral medication ( dysphagia etc . ) 6 . Patients pleural effusion ascites , cause respiratory syndrome ( CTCAE Grade 2 high dyspnea [ Grade 2 dyspnea refers Shortness breath small amount activity , affect Instrumental activity daily life ] ) 7 . Patients underwent major surgical treatment，open biopsy significant traumatic injury within 28 day prior assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>